Here, we discovered an elevated expression of HER3 in approximately half of the TNBC clinical samples and cell lines tested, and high HER3 expression significantly associated with poor OS and RFS in breast cancer patients with basal-like tumors (Fig. 1). This evidence concerns the gene ERBB3 and breast cancer.